Updated NCCN guidelines now recommend rusfertide as a Category 1 option for both low- and high-risk polycythemia vera.
Related to this article
An observational analysis showed a long-term OS benefit with Orca-T in adult patients undergoing allogeneic transplantation for hematologic malignancies.
FDA has granted fast track designation to LYT-200 plus a hypomethylating agent in relapsed/refractory high-risk myelodysplastic syndromes.
The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.
Advertisement
Advertisement
Trending on OncLive
1
Dr Kahl on Frontline Strategies for Avoiding Autologous Transplant in MCL
2
FDA MCGP Panel Vote Backs Galleri Multi-Cancer Early Detection Test
3
Positioning Artificial Intelligence to Help Explain Unexpected Cancer Trial Outcomes
4
Study Shows Reprogramming Thyroid Tumors May Improve CAR-T Cell Therapy
5